164 related articles for article (PubMed ID: 26178350)
1. [Survival and prognosis of patients with polycythemia vera: a study of 816 patients in a single Chinese center].
Bai J; Shi H; Ai L; Zhang L; Zhou Y; Li Z; Zhao Y; Sheng M; Li D; Li H; Qian L; Mi Y; Xiao Z; Zheng Y; Yang R; Xue Y
Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1364-8. PubMed ID: 26178350
[TBL] [Abstract][Full Text] [Related]
2. Incidence and risk factors for myelofibrotic transformation among 272 Chinese patients with JAK2-mutated polycythemia vera.
Bai J; Ai L; Zhang L; Yang FC; Zhou Y; Xue Y
Am J Hematol; 2015 Dec; 90(12):1116-21. PubMed ID: 26370613
[TBL] [Abstract][Full Text] [Related]
3. Thrombosis in patients with post-polycythemia vera myelofibrosis: incidence and risk factors.
Teng G; Zhou Y; Zhang Y; Hu N; Liu T; Han Y; Gao C; Zhang L; Bai J
Thromb Res; 2022 Apr; 212():38-43. PubMed ID: 35219930
[TBL] [Abstract][Full Text] [Related]
4. [Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].
Bai J; Xue YP; Zhang L; Li CH; Fan DM; Li B; Xu SC; Li DP; Sun XJ; Jiang B; Yang RC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):444-9. PubMed ID: 21518505
[TBL] [Abstract][Full Text] [Related]
5. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
6. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.
Passamonti F; Rumi E; Pietra D; Elena C; Boveri E; Arcaini L; Roncoroni E; Astori C; Merli M; Boggi S; Pascutto C; Lazzarino M; Cazzola M
Leukemia; 2010 Sep; 24(9):1574-9. PubMed ID: 20631743
[TBL] [Abstract][Full Text] [Related]
8. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis.
Passamonti F; Rumi E; Caramella M; Elena C; Arcaini L; Boveri E; Del Curto C; Pietra D; Vanelli L; Bernasconi P; Pascutto C; Cazzola M; Morra E; Lazzarino M
Blood; 2008 Apr; 111(7):3383-7. PubMed ID: 18187660
[TBL] [Abstract][Full Text] [Related]
9. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2017 Jan; 92(1):94-108. PubMed ID: 27991718
[TBL] [Abstract][Full Text] [Related]
10. [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].
Bai J; Xue YP; Ye L; Yao JF; Zhou CL; Qian LS; Yang RC; Li HY; Zhang HY; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):685-8. PubMed ID: 18399175
[TBL] [Abstract][Full Text] [Related]
11. [Overall survival and prognosis of patients with polycythemia vera: an analysis based on 906 patients from a single center].
Liu D; Xu ZF; Zhang PH; Ma J; Qin TJ; Qu SQ; Sun XJ; Li B; Pan LJ; Jia YJ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):898-903. PubMed ID: 35045650
[No Abstract] [Full Text] [Related]
12. The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis.
Helbig G; Wieczorkiewicz A; Woźniczka K; Wiśniewska-Piąty K; Rusek A; Kyrcz-Krzemień S
Med Oncol; 2012 Dec; 29(4):2379-84. PubMed ID: 22383244
[TBL] [Abstract][Full Text] [Related]
13. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A; Barbui T
Am J Hematol; 2023 Sep; 98(9):1465-1487. PubMed ID: 37357958
[TBL] [Abstract][Full Text] [Related]
15. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
16. Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China.
Bai J; Xue Y; Ye L; Yao J; Zhou C; Shao Z; Qian L; Yang R; Li H; Zhang H; Zheng Y
Int J Hematol; 2008 Dec; 88(5):530-535. PubMed ID: 19002391
[TBL] [Abstract][Full Text] [Related]
17. Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients.
Stein BL; Williams DM; Rogers O; Isaacs MA; Spivak JL; Moliterno AR
Exp Hematol; 2011 Jan; 39(1):95-101. PubMed ID: 20888389
[TBL] [Abstract][Full Text] [Related]
18.
Sassi H; Menif S; Ammar SB; Farrah A; Othmen HBH; Amouri H
Pan Afr Med J; 2021; 39():194. PubMed ID: 34603575
[TBL] [Abstract][Full Text] [Related]
19. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
20. Where to Turn for Second-Line Cytoreduction After Hydroxyurea in Polycythemia Vera?
Nazha A; Gerds AT
Oncologist; 2016 Apr; 21(4):475-80. PubMed ID: 26975864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
